

Supporting Information

Wastewater monitoring outperforms case numbers as a tool to track COVID-19 incidence dynamics when test positivity rates are high

Xavier Fernandez-Cassi¹, Andreas Scheidegger², Carola Bänziger², Federica Cariti¹, Alex Tuñas Corzon¹, Pravin Ganesanandamoorthy², Joseph C. Lemaitre³, Christoph Ort², Timothy R. Julian^{2,4,5}, Tamar Kohn^{1*}

¹ Laboratory of Environmental Chemistry, School of Architecture, Civil and Environmental Engineering, École Polytechnique Fédérale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland

² Swiss Federal Institute of Aquatic Science and Technology (Eawag), 8600 Dübendorf, Switzerland

³ Laboratory of Ecohydrology, School of Architecture, Civil and Environmental Engineering, École Polytechnique Fédérale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland

⁴ Swiss Tropical and Public Health Institute, CH-4051 Basel, Switzerland

⁵ University of Basel, CH-4051 Basel, Switzerland

10 pages, 3 tables, 8 figures

Contents

Text S1. Deconvolution to estimate daily number of infections

Table S1. RT-qPCR primers, probes and reaction conditions used in this work

Table S2. RT-qPCR assay efficiencies, limits of detection, and R² of standard curves

Table S3. Check-list of experimental details as requested by MIQE guidelines

Figure S1. Positivity rate in Switzerland during the first wave of the pandemic

Figure S2. C_q values measured in RNA extracts spiked with synthetic SARS-CoV-2 RNA reference material

Figure S3. SARS-CoV-2 N1 concentrations measured by RT-qPCR in biological and technical replicates

Figure S4. Recovery of three surrogate viruses simultaneously spiked into seven wastewater samples

Figure S5. Recovery of MHV (Lausanne and Lugano) or Sendai virus (Zurich) in longitudinal samples from the three WWTPs studied.

Figure S6. Daily load of PMMoV in Lausanne, Lugano and Zurich

Figure S7. SARS-CoV-2 N1 and N2 concentrations at each WWTP from February 26 to April 30, 2020

Figure S8. Comparison of the SARS-CoV-2 N1 and PMMoV RNA concentrations measured per ml of wastewater

References

Text S1. Deconvolution to estimate daily number of infections

The SARS-CoV-2 loads in wastewater and the daily confirmed cases are aggregated quantities. An aggregated quantity A_t observed on day t is the weighted sum all previous numbers of infections I . The weights w are given as function of the time since infection, τ :

$$A_t \approx \sum_{\tau=0}^{\infty} w(\tau) \cdot I_{t-\tau} \approx \sum_{\tau=0}^{\tau_{max}} w(\tau) \cdot I_{t-\tau}$$

As the weight decays with a larger τ the sum can be truncated at τ_{max} with a small error.

Based on the relationship from above we can estimate the infections $\mathbf{I} = (I_0, I_1, \dots, I_T)$ in a time interval $[0, \dots, T]$ from the set of observed aggregated quantities $\{A_t, t \in T_{obs}\}$. Note that the observation time points of A_t may be irregularly spaced in time. The loss function to minimize over \mathbf{I} is

$$\min_{\mathbf{I}} \sum_{t \in T_{obs}} \left(A_t - \sum_{\tau=0}^{\tau_{max}} w(\tau) \cdot I_{t-\tau} \right)^2 + \gamma \sum_{\tau=1}^{\tau_{max}} (I_{\tau} - I_{\tau-1})^2$$

with the constraint that all $I_{\tau} \geq 0$. The second term penalizes large deviations between successive infections and also ensures a unique solution. The larger the penalty term γ is chosen, the smoother change the resulting estimates over time.

This model can be seen as a non-negative ridge regression. We implemented it using the R-package CVXR for convex optimization.

Table S1. RT-qPCR primers, probes and PCR reaction conditions used in this work.

Virus	Ref	Primer name	Sequence (5'→3')	Primer concentration	Thermocycling protocol	Gene	Amplicon size (position)	Accession number
PMMoV	1, 2	PMMV-FP1-rev	5'-GAGTGGTTTGACCTTAACGTTTGA-3'	0.4 μM	RT at 55°C for 1h, 10 minutes at 95°C followed by 45 cycles of 95°C for 15s and 60°C for 60s	Replication-associated protein	68 (1878-1945)	NC_003630
		PMMV-RP1	5'-TTGTCGGTTGCAATGCAAGT-3'	0.4 μM				
		PMMV-Probe1	5'-FAM-CCTACCGAAGCAAATG-MGB-3	0.2 μM				
Sendai virus	This study	Sendai_F_2020	5'-GAGGTATAGGAGTCCCTGAAGT-3'	0.4 μM	RT at 48°C for 1h, 5 minutes at 95°C followed by 45 cycles of 95°C for 15s and 60°C for 30s	L gene - RNA polymerase protein	113 (13609-13726)	M30204
		Sendai_R_2020	5'-GCTCTAGTCTGATGTCCCAAAG-3'	0.4 μM				
		Sendai_P_2020	5'-FAM-TCCCGAGGCAGATAATGCACTGTT-ZEN/Iowa Black-3	0.2 μM				
SARS-CoV-2 (N1)	3	2019-nCoV_N1-F	5'-GACCCCAAATCAGCGAAAT-3'	0.5 μM	RT at 55°C for 1h, 10 minutes at 95°C followed by 45 cycles of 95°C for 15s and 55°C for 30s	Nucleocapsid phosphoprotein	72 (28287-28358)	NC_045512
		2019-nCoV_N1-R	5'-TCTGGTTACTGCCAGTTGAATCTG-3'	0.5 μM				
		2019-nCoV_N1-P	5'-FAM-ACCCCGCATTACGTTTGGTGGACC-ZEN/Iowa Black-3'	0.125 μM				
SARS-CoV-2 (N2)	3	2019-nCoV_N2-F	5'-TTACAAACATTGGCCGAAA-3'	0.5 μM	RT at 55°C for 1h, 10 minutes at 95°C followed by 45 cycles of 95°C for 15s and 55°C for 30s	Nucleocapsid phosphoprotein	67 (29164-29230)	NC_045512
		2019-nCoV_N2-R	5'-GCGCGACATTCGGAAGAA-3'	0.5 μM				
		2019-nCoV_N2-P	5'-FAM-ACAATTTGCCCCAGCGCTTCAG-ZEN/Iowa Black-3	0.125 μM				
MHV	4	MHV_F	5'-GGAACTTCTCGTTGGGCATTATACT-3'	0.3 μM	RT at 50°C for 1h, 5 minutes at 95°C followed by 45 cycles of 95°C for 15s and 60°C for 60s	Membrane protein	108 (29045-29152)	AY700211
		MHV_R	5'-ACCACAAGATTATCATTTTCACAACATA-3'	0.3 μM				
		MHV_P	5'-FAM-ACATGCTACGGCTCGTGTAAACCGAAGTGT-BHQ-3'	0.4 μM				
φ6	Adapted from 5	Phi6_F	5'-TGCGCGCGGTCAAGAG-3'	0.4 μM	RT at 50°C for 1h, 10 minutes at 95°C followed by 40 cycles of 95°C for 15s and 60°C for 1 min	Nucleocapsid protein (Segment S)	100 (429-528)	DQ785287
		Phi6_R	5'-GGATGATTCTCCAGAAGCTGCT-3'	0.4 μM				
		Phi6_P	5'-FAM-GTCGCAGGTCTGACT-BHQ-3'	0.08 μM				

Table S2. RT-qPCR assay efficiencies, limits of detection, and R² of standard curves.

Target	Efficiency [%]	LOD [gc/ml, (gc/reaction)]	Slope / intercept of standard curve	R ² of pooled standard curve	Number of standard curves in pool
SARS-CoV-2 N1	112	4.2 (13)	-3.07 / 38.24	0.97	21
SARS-CoV-2 N2	106	2.6 (8)	-3.18 / 39.14	0.95	16
MHV	98	3.2 (10)	-3.36 / 41.08	0.99	11
φ6	98	16 (50)	-3.37 / 39.52	0.99	3
Sendai virus	94	1.6 (5)	-3.47 / 38.87	0.99	4

Table S3. Check-list of experimental details as requested by MIQE guidelines⁶

ITEM TO CHECK	Provided (Y/N)	CHECKLIST
EXPERIMENTAL DESIGN		
Definition of experimental and control groups	Y	provided in methods section
Number within each group	Y	provided in methods section
SAMPLE		
Description	Y	provided in methods section
Microdissection or macrodissection	N	N/A
Processing procedure	Y	provided in methods section
If frozen - how and how quickly?	Y	provided in methods section
If fixed - with what, how quickly?	N	N/A
Sample storage conditions and duration	Y	provided in methods section
NUCLEIC ACID EXTRACTION		
Procedure and/or instrumentation	Y	provided in methods section
Name of kit and details of any modifications	Y	provided in methods section
Details of DNase or RNase treatment	N	N/A
Contamination assessment (DNA or RNA)	Y	provided in methods section
Nucleic acid quantification	Y	provided in methods section and SI
Instrument and method	Y	provided in methods section
RNA integrity method/instrument	N	not done
RIN/RQI or Cq of 3' and 5' transcripts	N	not done
Inhibition testing (Cq dilutions, spike or other)	Y	provided in methods section
REVERSE TRANSCRIPTION		
Complete reaction conditions	Y	provided in methods section
Amount of RNA and reaction volume	Y	provided in methods section
Priming oligonucleotide (if using GSP) and concentration	Y	provided in SI
Reverse transcriptase and concentration	Y	provided in SI
Temperature and time	Y	provided in SI
qPCR TARGET INFORMATION		
Sequence accession number	Y	Published assays or provided in SI
Amplicon length	Y	Published assays or provided in SI
<i>In silico</i> specificity screen (BLAST, etc)	N	not provided
Location of each primer by exon or intron (if applicable)	N	N/A
What splice variants are targeted?	N	N/A
qPCR OLIGONUCLEOTIDES		
Primer sequences	Y	provided in SI
Probe sequences	Y	provided in SI
Location and identity of any modifications	N	N/A
qPCR PROTOCOL		
Complete reaction conditions	Y	provided in SI
Reaction volume and amount of RNA	Y	provided in methods section
Primer, (probe), Mg ²⁺ and dNTP concentrations	Y	provided in SI and according to kit instructions
Polymerase identity and concentration	Y	According to kit instructions
Buffer/kit identity and manufacturer	Y	provided in methods section
Additives (SYBR Green I, DMSO, etc.)	Y	provided in methods section
Complete thermocycling parameters	Y	provided in SI
Manufacturer of qPCR instrument	Y	provided in SI
qPCR VALIDATION		
Specificity (gel, sequence, melt, or digest)	N	N/A
For SYBR Green I, Cq of the NTC	N	N/A
Standard curves with slope and y-intercept	Y	provided in SI
PCR efficiency calculated from slope	Y	provided in results section and SI
R ² of standard curve	Y	provided in results section and SI
Linear dynamic range	N	Not assessed
Cq variation at lower limit	N	Not determined
Evidence for limit of detection	Y	provided in methods section
DATA ANALYSIS		
qPCR analysis program (source, version)	Y	provided in methods section
Cq method determination	Y	provided in methods section
Outlier identification and disposition	N	N/A
Results of NTCs	Y	provided in results section
Justification of number and choice of reference genes	N	N/A
Description of normalisation method	N	N/A
Number and concordance of biological replicates	Y	provided in methods section
Number and stage (RT or qPCR) of technical replicates	Y	provided in methods section
Repeatability (intra-assay variation)	Y	provided in results section and SI
Statistical methods for result significance	Y	provided in methods section
Software (source, version)	Y	provided in methods section




Figure S1: Positivity rate in Switzerland during the first wave of the pandemic. Data source: Swiss Federal Office of Public Health.




Figure S2. Cq values measured in RNA extracts spiked with synthetic SARS-CoV-2 RNA reference material. Dashed lines indicate the median Cq for a given site. Dotted lines indicate the median ± 1.5 Cq, considered as the range with minimal PCR inhibition.




Figure S3. SARS-CoV-2 N1 concentrations measured by RT-qPCR (expressed as gc/reaction) in biological (a) and technical (b) replicates. One PCR reaction corresponds to 5 μ l of RNA extract, or 3.125 ml of wastewater. The shaded areas indicate the standard error associated with the regression line. Only measurements > LOD were considered.




Figure S4: Recovery of three surrogate viruses (MHV, Sendai virus and Φ 6) simultaneously spiked into seven wastewater samples. Each wastewater sample was processed and analyzed in duplicate. Panel a) Overview over all recoveries measured. Panels b-d) Paired comparison between recoveries measured by the three surrogates considered.




Figure S5. a) Recovery of MHV (Lausanne and Lugano) or Sendai virus (Zurich) in longitudinal samples from the three WWTPs studied. Each sample was processed and analyzed in duplicate. b) Violin plots show the kernel probability density (i.e. the proportion of data located along the range of recovery values, smoothed by a kernel estimator). Inside, boxplots show the median and interquartile range.




Figure S6. Daily load of PMMoV in Lausanne, Lugano and Zurich. Each sample was processed and analyzed in duplicate.




Figure S7. SARS-CoV-2 N1 and N2 concentrations at each WWTP from February 26 to April 30, 2020. All biological and technical replicates are plotted as individual data points. Dashed lines indicate the LOD for the N1 (4.2 gc/ml) and N2 (2.6 gc/ml) in wastewater.




Figure S8. Comparison of the SARS-CoV-2 N1 and PMMoV RNA concentrations measured per ml of wastewater. Because the Zurich WWTP mostly yielded N1 concentrations < LOD, this site was not included in the graph.

References

- (1) Haramoto, E.; Kitajima, M.; Kishida, N.; Konno, Y.; Katayama, H.; Asami, M.; Akiba, M. Occurrence of pepper mild mottle virus in drinking water sources in Japan. *Appl. Environ. Microbiol.* **2013**, *79*, 7413–7418.
- (2) Zhang, T.; Breitbart, M.; Lee, W. H.; Run, J.-Q.; Wei, C. L.; Soh, S. W. L.; Hibberd, M. L.; Liu, E. T.; Rohwer, F.; Ruan, Y. RNA viral community in human feces: prevalence of plant pathogenic viruses. *PLoS Biol.* **2006**, *4*, e3.
- (3) Lu, X.; Wang, L.; Sakthivel, S. K.; Whitaker, B.; Murray, J.; Kamili, S.; Lynch, B.; Malapati, L.; Burke, S. A.; Harcourt, J.; et al. US CDC Real-Time Reverse Transcription PCR Panel for Detection of Severe Acute Respiratory Syndrome Coronavirus 2. *Emerging Infect. Dis.* **2020**, *26*.
- (4) Besselsen, D. G.; Wagner, A. M.; Loganbill, J. K. Detection of rodent coronaviruses by use of fluorogenic reverse transcriptase-polymerase chain reaction analysis. *Comp Med* **2002**, *52*, 111–116.
- (5) Gendron, L.; Verreault, D.; Veillette, M.; Moineau, S.; Duchaine, C. Evaluation of filters for the sampling and quantification of RNA phage aerosols. *Aerosol Sci. Technol.* **2010**, *44*, 893–901.
- (6) Bustin, S. A.; Benes, V.; Garson, J. A.; Hellemans, J.; Huggett, J.; Kubista, M.; Mueller, R.; Nolan, T.; Pfaffl, M. W.; Shipley, G. L.; et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. *Clin. Chem.* **2009**, *55*, 611–622.